287 related articles for article (PubMed ID: 26451508)
1. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.
Balestri M; Calati R; Souery D; Kautzky A; Kasper S; Montgomery S; Zohar J; Mendlewicz J; Serretti A
J Affect Disord; 2016 Jan; 189():224-32. PubMed ID: 26451508
[TBL] [Abstract][Full Text] [Related]
2. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
[TBL] [Abstract][Full Text] [Related]
3. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
[TBL] [Abstract][Full Text] [Related]
4. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review.
De Carlo V; Calati R; Serretti A
Psychiatry Res; 2016 Jun; 240():421-430. PubMed ID: 27155594
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
7. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
[TBL] [Abstract][Full Text] [Related]
9. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
[TBL] [Abstract][Full Text] [Related]
10. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
[TBL] [Abstract][Full Text] [Related]
11. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH
J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575
[TBL] [Abstract][Full Text] [Related]
12. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
[TBL] [Abstract][Full Text] [Related]
13. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
[TBL] [Abstract][Full Text] [Related]
14. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
[TBL] [Abstract][Full Text] [Related]
15. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
[TBL] [Abstract][Full Text] [Related]
16. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.
Kautzky A; Dold M; Bartova L; Spies M; Kranz GS; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Dikeos D; Rujescu D; Kasper S
Acta Psychiatr Scand; 2019 Jan; 139(1):78-88. PubMed ID: 30291625
[TBL] [Abstract][Full Text] [Related]
18. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
Fugger G; Bartova L; Dold M; Fabbri C; Fanelli G; Zanardi R; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110480. PubMed ID: 34826558
[TBL] [Abstract][Full Text] [Related]
19. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
Gobbi G; Ghabrash MF; Nuñez N; Tabaka J; Di Sante J; Saint-Laurent M; Vida S; Kolivakis T; Low N; Cervantes P; Booij L; Comai S
Int Clin Psychopharmacol; 2018 Jan; 33(1):34-43. PubMed ID: 28906325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
